Literature DB >> 8368224

Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone.

G E LaRochelle1, A G LaRochelle, R E Ratner, D G Borenstein.   

Abstract

PURPOSE: To assess the status of the hypothalamic-pituitary-adrenal (HPA) axis in cortico-steroid-treated patients whose prednisone dose had been tapered to physiologic doses. PATIENTS AND METHODS: The design of the study was a retrospective chart review of 50 consecutive patients receiving 10 mg or less of prednisone daily at a university teaching hospital rheumatology clinic. Patients were given a rapid adrenocorticotropic hormone stimulation test, with cortisol levels obtained at baseline and after intravenous administration of cosyntropin. Charts were reviewed for duration of therapy, highest, current, and total cumulative steroid dose, and average daily steroid dose in each month of the preceding 2 years.
RESULTS: Current steroid dose was the only significant indicator of HPA axis function. Patients receiving less than 5 mg of prednisone daily had a normal HPA axis response, whereas those receiving 5 mg or more had widely varied responses. Neither the total, the highest prednisone dose, nor the duration of therapy was a significant indicator of HPA axis recovery.
CONCLUSIONS: Spontaneous recovery of the HPA axis is usual for patients who are taking prednisone at daily doses of 5 mg or less. Return of normal HPA axis function can be achieved without alternate-day therapy in patients whose disease allows tapering to daily prednisone doses of 5 mg or less.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368224     DOI: 10.1016/0002-9343(93)90277-v

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  [Cortisone therapy today].

Authors:  Hanns Kaiser
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

2.  [Perioperative Addisonian crisis].

Authors:  C Martin; T Steinke; M Bucher; C Raspé
Journal:  Anaesthesist       Date:  2012-06-15       Impact factor: 1.041

3.  The timing of glucocorticoid administration in rheumatoid arthritis.

Authors:  N G Arvidson; B Gudbjörnsson; A Larsson; R Hällgren
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

Review 4.  [Adrenal cortex and steroids. Supplementary therapy in the perioperative phase].

Authors:  A S Milde; B W Böttiger; M Morcos
Journal:  Anaesthesist       Date:  2005-07       Impact factor: 1.041

Review 5.  Preoperative optimization of crohn disease.

Authors:  Amit Sharma; Bertram T Chinn
Journal:  Clin Colon Rectal Surg       Date:  2013-06

6.  Hydrocortisone improves somnolence without hypotension in the postpartum period.

Authors:  Nada Usta-Makkaoui; Timothy L Lacy; Neil Roy Connelly
Journal:  J Anesth       Date:  2008-02-27       Impact factor: 2.078

7.  Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency.

Authors:  Sofie Jespersen; Birte Nygaard; Lars Østergaard Kristensen
Journal:  Eur Thyroid J       Date:  2015-10-27

8.  Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.

Authors:  Rebecca M Joseph; Ann Louise Hunter; David W Ray; William G Dixon
Journal:  Semin Arthritis Rheum       Date:  2016-03-09       Impact factor: 5.532

9.  A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.

Authors:  Dora Liu; Alexandra Ahmet; Leanne Ward; Preetha Krishnamoorthy; Efrem D Mandelcorn; Richard Leigh; Jacques P Brown; Albert Cohen; Harold Kim
Journal:  Allergy Asthma Clin Immunol       Date:  2013-08-15       Impact factor: 3.406

10.  Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study.

Authors:  Yvan Jamilloux; Eric Liozon; Gregory Pugnet; Sylvie Nadalon; Kim Heang Ly; Stephanie Dumonteil; Guillaume Gondran; Anne-Laure Fauchais; Elisabeth Vidal
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.